Therapeutic Advances in Cardiovascular Disease JCR impact factor overview
Automatically generated from the journal record shown on this page.
Clarivate JCR impact factor overview
Therapeutic Advances in Cardiovascular Disease is listed in this directory with bibliometric information for 2025. It is published by SAGE PUBLICATIONS LTD. The database records a Journal Impact Factor of 2.200, presented as a Clarivate Journal Citation Reports (JCR)-based metric. Its listed JCR Impact Factor quartile is Q2.
Ranking and quartile
The recorded JCR Impact Factor category rank is 111 out of 230 journals in its listed category. A Q2 designation describes the journal’s position within its subject category; it should not be used as a direct measure of the quality of an individual article.
Citation profile
The record contains 741 total citations, 13 total articles, 27 citable items. The five-year Impact Factor is 2.900, which is 0.700 points above the listed standard Journal Impact Factor. These values use different citation windows and should be interpreted together rather than as a direct trend. The Journal Impact Factor without journal self-citations is recorded as 2.200. The Journal Citation Indicator is listed as 0.540.
Citation half-life
The cited half-life is recorded as 7.5 years, describing the median age of articles cited in the reporting year. The citing half-life is 6.3 years, reflecting the median age of references used by the journal’s articles.
Journal identifiers and verification
Therapeutic Advances in Cardiovascular Disease is identified in this record by print ISSN 1753-9447 and electronic ISSN 1753-9455. Use the ISSN when checking library catalogues, publisher records, indexing databases, or the official Clarivate Journal Citation Reports entry.
Complete journal information
All values below come directly from the database record.
| Journal name | Therapeutic Advances in Cardiovascular Disease |
|---|---|
| Abbreviated journal | THER ADV CARDIO DIS |
| Publisher | SAGE PUBLICATIONS LTD |
| Metric year | 2025 |
| Overall rank | 7,420 |
| ISSN | 1753-9447 |
| eISSN | 1753-9455 |
| Total cites | 741 |
| Total articles | 13 |
| Citable items | 27 |
| Cited half-life | 7.5 years |
| Citing half-life | 6.3 years |
| JCR-based Journal Impact Factor | 2.200 |
| 5-Year Impact Factor | 2.900 |
| Impact Factor without journal self-cites | 2.200 |
| Journal Citation Indicator | 0.540 |
| JCR Impact Factor quartile | Q2 |
| JCR category rank | 111/230 |
| Database record updated |
Frequently asked questions
What is the 2025 JCR-based Journal Impact Factor of Therapeutic Advances in Cardiovascular Disease?
The Journal Impact Factor recorded in this directory as a Clarivate Journal Citation Reports (JCR)-based value for Therapeutic Advances in Cardiovascular Disease is 2.200 for the 2025 metric year.
What quartile is Therapeutic Advances in Cardiovascular Disease?
Therapeutic Advances in Cardiovascular Disease is listed in quartile Q2. Quartiles describe a journal’s position within a subject category and should be interpreted within that field.
Who publishes Therapeutic Advances in Cardiovascular Disease?
Therapeutic Advances in Cardiovascular Disease is listed as being published by SAGE PUBLICATIONS LTD.
Can a JCR Journal Impact Factor be used to judge an individual article?
No. The Journal Impact Factor is a journal-level citation measure reported in Clarivate Journal Citation Reports. It does not measure the quality, reliability or influence of every individual article published by that journal.
Related journal profiles
Additional records from the same publisher or with a similar listed JCR Impact Factor.